Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy | Zendy

Peter F. Wright | Zendy; Ruth A. Karron | Zendy; Robert B. Belshe | Zendy; Juliette Thompson | Zendy; James E. Crowe | Zendy; Thomas G. Boyce | Zendy; Lisa L. Halburnt | Zendy; George Reed | Zendy; Stephen S. Whitehead | Zendy; Edwin L. Anderson | Zendy; Alec E. Wittek | Zendy; Roberta Casey | Zendy; Maryna C. Eichelberger | Zendy; Bhagvanji Thumar | Zendy; Valerie B. Randolph | Zendy; Stephen A. Udem | Zendy; Robert M. Chanock | Zendy; Brian R. Murphy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy

Author(s) -

Peter F. Wright,

Ruth A. Karron,

Robert B. Belshe,

Juliette Thompson,

James E. Crowe,

Thomas G. Boyce,

Lisa L. Halburnt,

George Reed,

Stephen S. Whitehead,

Edwin L. Anderson,

Alec E. Wittek,

Roberta Casey,

Maryna C. Eichelberger,

Bhagvanji Thumar,

Valerie B. Randolph,

Stephen A. Udem,

Robert M. Chanock,

Brian R. Murphy

Publication year - 2000

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/315859

Subject(s) - virus , virology , attenuated vaccine , medicine , respiratory tract , respiratory system , immunology , respiratory tract infections , viral shedding , nasal administration , antibody , pneumovirinae , pneumovirus , vaccination , biology , paramyxoviridae , viral disease , virulence , biochemistry , gene

A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants-a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research